Nurse Practitioner, Gerontology · New York, NY
NPI
1528731890
Since 2021
Specialty
Nurse Practitioner, Gerontology
Code 363LG0600X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
425 E 61st St Fl 8
New York, NY, 10065
Phone (646) 962-2065
Groups this clinician bills Medicare through
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$2.2M
556 prescriptions
Company payments, 2025
$223
From 3 companies
Medicare prescription drug claims, 2024
In 2024, the drug Emily Yam prescribed most often to Medicare patients was Eliquis (Apixaban), with 153 prescriptions and refills. In total Emily Yam wrote 556 Medicare prescriptions that cost $2.2M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-20.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Eliquis Apixaban | 153 | 207 | 38 | $118K |
| Xarelto Rivaroxaban | 59 | 87 | 14 | $47K |
| Hydroxyurea Generic | 48 | 81 | 15 | $806 |
| Doptelet Avatrombopag Maleate | 26 | 26 | Under 11 | $525K |
| Promacta Eltrombopag Olamine | 25 | 25 | Under 11 | $125K |
| Jakafi Ruxolitinib Phosphate | 25 | 25 | Under 11 | $527K |
| Calquence Acalabrutinib Maleate | 20 | 20 | Under 11 | $293K |
| Brukinsa Zanubrutinib | 18 | 18 | Under 11 | $271K |
| Warfarin Sodium Generic | 17 | 38 | Under 11 | $114 |
| Imatinib Mesylate Generic | 15 | 23 | Under 11 | $218K |
| Everolimus Generic | 13 | 13 | Under 11 | $6,736 |
| Prednisone Generic | 12 | 18 | Under 11 | $47.35 |
| Levothyroxine Sodium Generic | 11 | 31 | Under 11 | $103 |
Brand drugs: 340 claims; generic drugs: - claims; opioid claims: 20.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Emily Yam $223 ($223 in general payments such as food, travel and fees) from 3 companies. The largest payer was Gilead Sciences, Inc. with $99.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.